In addition, the analogue 17-hydroxy Wortmannin decreases drug resistance by restoring TRAIL’s response through ameliorating PIK3C3-beclin 1 (BECN1) complex and autophagy activity in colon cancer cells (Dai et al., 2019). The gene discussed is BECN1; the disease is colonic neoplasm.